Log In
BCIQ
Print this Print this
 

Survivin UsiRNA formulated in a DiLA2 lipid-based delivery vehicle (MRNA-046)

  Manage Alerts
Collapse Summary General Information
Company Marina Biotech Inc.
DescriptionDuplex short interfering RNAs (siRNAs) modified with unlocked nucleobase analogs (UNA) formulated in a DiLA2 liposome formulation targeting survivin (BIRC5)
Molecular Target Survivin (BIRC5)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$11.1M

$1.0M

0


 Deals Details
Get a free BioCentury trial today